Clinical Trial Update: Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating intensified dosing of Cellcept (mycophenolate mofetil) in kidney transplant recipients with acute rejection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rejection of Renal Transplant

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Nova Scotia Health Authority | Conditions: Acute Rejection of Renal Transplant | Phase 4 | Status: COMPLETED